Recent studies have shown the importance of lifestyle measures in preventing or delaying the development of type 2 diabetes in people with impaired glucose tolerance (IGT). Lifestyle measures appear to be more beneficial than therapy with metformin, or acarbose, and the benefit is most likely to be mediated by reductions in insulin resistance. Several large, multi-centre cardiovascular studies have also been performed where the development of new diabetes has been a secondary end point, and some ACE inhibitors, angiotensin receptor antagonists, and statins also appear to prevent or delay the development of diabetes in at-risk patients. These may act by increasing insulin sensitivity, decreasing inflammatory markers, or by affecting other key components of the metabolic syndrome. This is being tested in ongoing studies in patients with IGT.
Tuomilehto J. , Lindstrom J., Eriksson JG et al. for the Finnish Diabetes Prevention Study Group.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343-50.
2.
Diabetes Prevention ProgramResearch Group.Reduction in the incidence of Type 2 diabetes with lifestyle or metformin. N Engl J Med2002; 346:393-403.
3.
Chiasson J-L. , Josse RG, Gomis R. et al. for the STOP-NIDDM Trial Research Group.Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002;359:2072-7.
4.
Diabetes Atherosclerosis InterventionStudy Investigators.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905-10.
5.
The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med2000;342:145-53.
6.
Dahlof B., Devereux RB, Kjeldsen S. et al. for the LIFE study group.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet2002;359:995-1003.
7.
Heart Outcomes prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253-9.
8.
Lindholm LH, Ibsen H., Dahlof B. et al. for the LIFE study group.Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:1004-10.
9.
Hansson L., Zanchetti A., Carruthers SG et al. for the HOT study group.Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998;351:1755-62.
10.
Shepherd J. , Cobbe SM, Ford I. et al. for the West of Scotland Coronary prevention Study Group.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995;333: 1301-07.
11.
Hansson L., Lindholm LH, Niskanen et al. for the Captopril Prevention Project (CAPPP) study group.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet1999;353:611-16.
12.
Eriksson J. , Lindstrom J., Valle T. et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland: study design and 1-year interim report on feasibility of the lifestyle intervention programme. Diabetologia1999;42:793-801.
13.
Yusuf S., Gerstein H., Hoogwerf B. et al. for the HOPE Study Investigators.Ramipril and the development of diabetes. JAMA2001;286:1882-5.
14.
Brunner HR, Gavras H.Angiotensin blockade for hypertension: a promise fulfilled. Lancet2002;359:990-1.
15.
Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996;335:1001-09.
16.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998;339:1349-57.
17.
Sacks FM, Tonkin AM, Shepherd J. et al. for the Prospective Pravastatin Pooling Project Investigators Group.Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation2000;102:1893-900.
18.
Freeman DJ, Norrie J., Sattar N. et al. Pravastatin and the development of diabetes. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study . Circulation2001;103:357-62.
19.
Haffner SMDo interventions to reduce coronary heart disease reduce the incidence of Type 2 diabetes? A possible role for inflammatory markers. Circulation2001;103:346-7.
20.
Freeman DJ, Norrie J., Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study . Diabetes2002;51:1596-600.
21.
Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) . Lancet2000;356:366-72.
22.
Ziccardi P. , Nappo F., Giugliano G. et al. Reduction in inflammatory cytokine concentrations and improvement in endothelial functions in obese women after weight loss over one year. Circulation2002 ;105:804-09.
23.
Eriksson J. , Taimela S., Koivisto VAExercise and the metabolic syndrome. Diabetologia1997;40:125-35.
24.
Krentz AJ, Bailey CJPharmacological treatment I In: Krentz AJ, Bailey CJ, Type 2 diabetes in practice. Royal Society of Medicine Press , London, 2001:125-40.
25.
Henriksen EJ , Jacob S.Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism1995;44:267-72.
26.
Lithell HOEffects of antihypertensives drugs on insulin, glucose and lipid metabolism . Diabetes Care1991;14:203-09.
27.
Mancini GB, Henry GC, Macaya C. et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation1996;94:258-65.
28.
Carlsson PO , Berne C., Jansson L.Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia1998;41:127-33.
29.
Ferrannini E., Seghieri G., Muscelli E.Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol1994;24(suppl 3):S61-9.
30.
Mullen MJ, Wright D., Donald AE et al. 2000. Atorvastatin but not L-arginine improves endothelial dysfunction in type I diabetes mellitus: a double blind study . J Am Coll Cardiol 2000;36:410-16.
31.
Evans AJ, Krentz AJRecent developments and emerging therapies for type 2 diabetes. Drugs in Research and Development1999;2:275-94.
